Slingshot members are tracking this event:

Novartis (NVS) to submit biosimilar Adalimumab to FDA for arthritis in second half of 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
NVS Community voting in process
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Adalimumab, Biosimilar, Fda Review